Household material hardship as a barrier to accessing sickle cell disease curative therapy
Colleen Kelly(Brown University), Kira Bona(Dana-Farber Cancer Institute), Sunyu Kang(Harvard University), Leanne Duhaney(Boston Children's Hospital), Anna Revette(Dana-Farber Cancer Institute), Natasha M. Archer(Boston Children's Hospital), Rahela Aziz‐Bose(Harvard University), Paul Morgan(University of Pittsburgh), Puja J. Umaretiya(The University of Texas Southwestern Medical Center)
Cited by 0
Related Papers
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
|Journal of Clinical Oncology|2016|754
Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma
|Journal of Clinical Oncology|2016|679
Effect of Fecal Microbiota Transplantation on Recurrence in Multiply Recurrent <i>Clostridium difficile</i> Infection
|Annals of Internal Medicine|2016|608